A novel biomineralized metal-organic framework delivery system demonstrated potential in suppressing myocardial fibrosis and enhancing cardiac function in preclinical models.
Hypothesis-generating for MOF nanoparticles in fibrosis; leaves open clinical translation pending validation.
A novel NH 2 -UiO-66@Cur@PCM delivery system was constructed. In vivo experiments show that the nanoparticles can effectively inhibit the process of myocardial fibrosis, highlighting the potential of MOF in cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: